Characteristics Associated to Lipodystrophy Syndrome among HIV-Infected Patients Naive and on Antiretroviral Treatment

Paulo R Alencastro1, Fernando H Wolff2, Fabiana Schuelter-Trevisol3, Maria Leticia Ikeda1,2, Ajácio B. M. Brandão4, Nemora T. Barcellos1,4 and Sandra C. Fuchs2,4,*

1Hospital Sanatório Partenon, Rio Grande do Sul State Department of Health, Av. Bento Gonçalves, 3722, Porto Alegre, RS 90650-001, Brazil
2Postgraduate Program in Epidemiology, School of Medicine, Universidade Federal do Rio Grande do Sul, R. Ramiro Barcelos 2600, Porto Alegre, RS 90035-003, Brazil
3Postgraduate Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul, R. Ramiro Barcelos 2350, Porto Alegre, RS 90035-003, Brazil
4National Institute for Health Technology Assessment (IATS/CNPq), Hospital de Clinicas de Porto Alegre, Centro de Pesquisa Clínica, R. Ramiro Barcelos 2350, Porto Alegre, RS 90035-003, Brazil

Abstract

Background: HIV-associated lipodystrophy involves changes in complex metabolic networks that are associated with increased cardiovascular risk. It has been associated with the use of combined antiretroviral treatment (cART), particularly Protease Inhibitors (PI) and thymidine analogs. This study aims to evaluate characteristics and use of ART associated with lipodystrophy, lipo hypertrophy, and lipoatrophy among HIV-infected patients.

Methods: A cross-sectional study was conducted in HIV-infected patients of both genders, aged 18 years or older, who sought care at an HIV/AIDS referral service for diagnostic confirmation or treatment between June 2006 and December 2008.

Results: 1240 out of 1295 patients with HIV infection were included. Among patients on cART, women had a higher risk of lipo hypertrophy than men, as well as a time since diagnosis of HIV greater than 6 years (versus <3 years). For lipoatrophy, age, education, lifestyle, and body mass index were associated with increased risk. Metabolic parameters were higher among patients on ART, and cART and PI use were independently associated with lipo hypertrophy, lipoatrophy and lipodystrophy. The use of PI can be regarded as responsible for 13% of the association of ART and lipodystrophy, and of 11.5% for the thymidine analogs use, independent of gender, skin color, smoking, CD4, and BMI.

Conclusions: Risk factors for lipodystrophy, lipoatrophy and lipo hypertrophy are marked among ART users, but also among ART naïve patients.

Keywords: HIV; Lipodystrophy; Lipo hypertrophy; Lipoatrophy; Risk factors; HAART; Dyslipidemia

Introduction

The introduction of combined antiretroviral treatment (cART) of HIV was a milestone in the struggle to reduce the rate of morbidity associated with progression of disease toward advanced stages of immunosuppression [1]. HIV-infected patients with lipodystrophy exhibit clinical changes in complex metabolic networks that are associated with increased cardiovascular risk [2-6].

Lipodystrophy is characterized by dyslipidemia, visceral adiposity, and subcutaneous abdominal fat buildup with peripheral wasting. The features of fat redistribution are variable, but they are usually detected by accumulation of fat in the abdomen, chest, breasts, or dorsocervical fat pad (“buffalo hump”), signs of lipohypertrophy, and the wasting of the face, anterior and lateral region of the neck, legs, arms or buttocks, known as lipoatrophy [3,5,7,8]. The HIV-associated lipodystrophy is a multifactorial disorder due to the interaction between virus and host factors related to cART [9]. Lipodystrophy appears to be mediated, even before the start of cART, by the increased inflammatory cytokines resulting from the HIV infection itself and, later, by use of cART [6]. The Protease Inhibitor (PI) reduces the proliferation and differentiation of adipocytes and increases lipolysis by inhibition of CRABP-1 (cytoplasmic retinoic-acid binding protein type1), blocking the activation of transcription factors linked to the PPAR-γ (peroxizone proliferator activated receptor type gamma) [10]. Nucleoside Reverse Transcriptase Inhibitor (especially stavudine-D4T) induce mitochondrial dysfunction [11], leading to lipoatrophy [6,9,10]. The prevalence of lipodystrophy ranges from 18 to 83%, depending on the criteria used for diagnosis [12] and along with body fat changes, there are metabolic abnormalities including increased levels of triglycerides, LDL cholesterol, total cholesterol, glucose, and insulin, and decreased level of HDL cholesterol [3,5].

There are few data available on ART among HIV-infected people living in low and middle income countries [13,14]. In Senegal, thymidine analogs and PI are among the most commonly used drugs for the treatment of HIV-infected patients, which contributes to the prevalence of lipodystrophy 65% [14]. In another African study, conducted in Rwanda, the prevalence of lipodystrophy was 34%, and the patients were not in treatment with PI [13]. Few studies conducted in Brazil have assessed the prevalence and risk factors of lipodystrophy in HIV-infected patients who are not participating of randomized clinical trials [15]. In a study conducted in São Paulo, lipodystrophy was detected in...
64.3% of patients, 37.4% had lipoatrophy and lipohypertrophy 49.2% [16]. In this study we aimed to verify characteristics associated to lipodystrophy syndrome among HIV-infected patients naïve and on ART.

Methods

This cross-sectional study included men and women living with HIV/AIDS, aged 18 years or older, who sought HIV diagnostic confirmation or treatment at the HIV/AIDS outpatient care center of Hospital Sanatório Partenon. Pregnant women, patients with intellectual disability, and incarcerated or institutionalized persons were excluded from the study. The study was approved by the institutional review board of the Hospital de Clínicas de Porto Alegre, which is accredited by the Office of Human Research Protections. All participants signed a consent form.

Study variables

We used a standardized questionnaire to collect data on demographic (age, gender, skin color), socioeconomic (years at school), lifestyle characteristics (smoking and physical activity), HIV-infection related variables: use of antiretroviral treatment (ART), time since HIV diagnosis (categorized as <3, 3-5, and ≥ 6), and signs and symptoms of lipodystrophy. Age was calculated by subtracting the birth date from the date of interview; with analysis conducted as a categorical variable (18-34, 35-49, and 50-78 years) for the description and as a continuous variable to detect independent associations; skin color was self-reported and categorized as Caucasian or non-Caucasian; and education was measured as the number of years at school, analyzed as a categorical variable (0-4, 5-8, 9-11, or ≥ 12 years) in the description and as a continuous variable to assess independent associations. Lifetime tobacco exposure was calculated in former and current smokers by the number of packs smoked per day (1 pack=20 cigarettes) multiplied by the number of years of smoking [17-19]. For purposes of analysis, former or current smokers were stratified into those with ≥ 20 and those with <20 pack-years. Physical activity was estimated by the IPAQ (International Physical Activity Questionnaire) instrument [20], and subjects were considered physically active if they engaged weekly in at least 150 minutes of physical activity [21,22]. Body mass index (BMI, kg/m²) was assessed as a categorical variable for the description and as a continuous variable in order to detect independent associations. The use of ART was investigated during anamnesis and confirmed or treatment at the HIV/AIDS outpatient care center of Hospital Sanatório Partenon. Pregnant women, patients with intellectual disability, and incarcerated or institutionalized persons were excluded from the study. The study was approved by the institutional review board of the Hospital de Clínicas de Porto Alegre, which is accredited by the Office of Human Research Protections. All participants signed a consent form.

Data collection

Data were collected during routine visits, and consisted of blood pressure measurement and anthropometry. Weight (kg) and height (m) were measured, with patients in barefoot and wearing light clothes. Body mass index (BMI) was calculated by dividing the weight (in kg) by the height (in meters) squared. Waist circumference was measured midway between the iliac crest and low costal rib margin [29,30]. Hip circumference was measured at the greater trochanter and the point of greatest gluteal protuberance.

Facial skin fold thickness was measured with a scientific skin fold caliper in the infra-orbital, buccal and submandibular regions. Measurements were done in duplicate and the average was used for determine the abnormal cutoffs.

Sample size calculation and statistical analysis

Sample size calculation was based on an estimate that 17% of ART naïve patients and 25% of patients on ART would have lipodystrophy. For a statistical power of 80% and 95% confidence interval, with an unexposed to exposed ratio of 0.5, in order to detect a risk ratio (RR) of 1.5, it was needed to enroll at least 984 patients. The sample size was increased in 30% to take into account confounding factors in multivariate analysis.

Pearson’s chi-squared test was used for categorical variables and analysis of variance, for continuous variables. All analyses were performed in the Statistical Package for the Social Sciences (SPSS) version 14.0 software environment (SPSS Inc., Chicago, Illinois, USA). Modified Poisson regression was used to test for associations between risk factors and the presence of lipohypertrophy, lipoatrophy, and lipodystrophy, calculating adjusted prevalence ratios and 95% confidence intervals. A trend toward association was defined as 0.05<P<0.1.

The analysis was based on a hierarchical framework, which provides a strategy to conduct multivariate analysis in studies where determinants of disease are sought, there are hierarchical relationships among determinants, and these aspects are taken into consideration as well as the literature [29]. The information allowed to testing some characteristics as continuous and categorical variables, and the best fit was used in each statistical test. Characteristics were aggregated into three sets of variables, which contained different hierarchical levels of determination, including in the first level: socioeconomic (education) and biological characteristics (gender, age, and skin color), in the second: lifestyle (smoking and physical activity), and in the third level: HIV-related characteristics (viral load, CD4, time since HIV diagnosis, and BMI). These potential determinants are likely to lead to lipohypertropy, lipoatrophy, and lipodystrophy (Figure 1). At each level, variables were included in the model based on the strength
of association in the crude analyses (P value<0.2), and one regression equation was fitted for each hierarchical level, also including variables from higher levels of determination [30]. We conducted separate analyses according to the ART status (on ART and ART naïve) and for each clinical outcome.

Results

The cohort included a consecutive sample of 1240, out of 1295, HIV-infected subjects eligible to participate; 15 refused to take part, and 40 were excluded due to age, incarceration, or pregnancy. Participants were, on average, 38.6 ± 10.1 years old. Approximately half were men, most were Caucasians. Most patients had received ART (65.7%) during lifetime, and among those on ART the majority used PI (42.6%), thymidine analogs (31.0%), and d-drugs (31.9%).

Table 1 describes characteristics of patients receiving ART and ART naïve subjects. Patients on cART were older (P<0.001), smokers (P=0.004), had increased BMI (P=0.003), longer time since HIV infection diagnosis (P<0.001), had detectable viral load (P <0.001), CD4 counts below 350 cells/mm³ (P<0.001), and metabolic parameters were higher than those patients who were cART naïve. There were 51 patients on ART and six, who had not started treatment at the time of the study enrollment, with advanced stages of AIDS.

The prevalence of lipohypertrophy was 50.2% among patients on ART and 37.9% among ART naïve patients, 58.2% and 43.8%, respectively, for lipatrophy, and 79.1% and 64.7%, respectively, for lipodystrophy. Table 2 presents the distribution of characteristics associated with lipohypertrophy, lipatrophy, and lipodystrophy separated for patients on cART and ART naïve.

Table 3 shows the characteristics independently associated with risk of lipohypertrophy, lipatrophy and lipodystrophy in patients on ART. The selection of confounding factors for lipohypertrophy were: gender and age (first level), smoking (second level), and BMI, CD4, and viral load (third level); for lipatrophy: gender, skin color, and education (first level), none for the second level, and BMI and time since diagnosis of HIV (third level); for lipodystrophy: age, skin color, and education (first level), none for the second level, and BMI and time since diagnosis of HIV (third level). Women had 58% higher risk of lipohypertrophy than men (P<0.001), independent of age. After control for age and gender, smoking status remained as a protective factor for lipohypertrophy while an increase in one unit of BMI resulted in 7% elevated risk of lipohypertrophy, after the control for biological, lifestyle, and HIV-related variables. Time since HIV diagnosis was not associated with lipohypertrophy. After the control for gender, skin color, and educations, characteristics as non-white skin color increased 26% the risk of lipatrophy, in comparison to white ones (P<0.001), while education was inversely associated (P<0.001). Body mass index was inverse and independently associated to lipatrophy (P<0.001) and longer time since the HIV diagnosis was a risk factor. Lipodystrophy
### Table 2: Distribution of characteristics associated with lipohypertrophy, lipoatrophy, and lipodystrophy in HIV-infected patients according to ART treatment status [n (%)].

| Characteristic                  | ART naïve | ART on ART | P value |
|---------------------------------|-----------|------------|---------|
| **Age (years)**                 |           |            |         |
| 18-34                           | 147 (65.9)| 84 (37.7)  | 0.13    |
| 35-49                           | 99 (64.7) | 70 (35.6)  | 0.11    |
| 50-78                           | 29 (59.2) | 18 (36.7)  | 0.4     |
| **Gender**                      |           |            |         |
| Male                            | 138 (66.3)| 137 (63.1) | 0.7     |
| Female                          |           |            |         |
| **Education (years)**           |           |            |         |
| 0-4                             | 66 (64.7) | 56 (54.9)  | 0.13    |
| 5-8                             | 114 (72.2)| 74 (48.6)  | 0.4     |
| 9-11                            | 67 (58.3) | 42 (36.5)  | 0.7     |
| ≥12                             | 28 (56.0) | 20 (40.9)  | 0.8     |
| **Smoking (pack-years)**        |           |            |         |
| 0                               | 16 (38.5) | 12 (27.5)  | <0.001  |
| 1-19                            | 12 (27.5) | 8 (18.2)   | <0.001  |
| ≥20                             | 66 (14.6) | 51 (11.4)  | <0.001  |
| **Physical activity (min/week)**|          |            |         |
| ≥150                            | 168 (66.4)| 121 (47.8)| 0.02    |
| <150                            | 107 (62.2)| 65 (37.8)  | 0.06    |
| **Body mass index (kg/m²)**     |           |            |         |
| <18.5                           | 11 (100.0)| 11 (100.0)| <0.001  |
| 18.5-24.9                       | 134 (65.7)| 109 (53.4)| 0.5     |
| 25-29.9                         | 82 (55.4) | 48 (32.4)  | 0.4     |
| ≥30.0                           | 48 (77.4) | 47 (75.8)  | 0.02    |
| **Time since diagnosis of HIV** |           |            |         |
| <3                              | 170 (62.0)| 121 (44.2)| 0.04    |
| 3-5                             | 63 (67.0) | 36 (38.3)  | 0.5     |
| ≥6                              | 42 (73.7) | 29 (50.9)  | 0.01    |
| **Viral load (copies/mL)**      |           |            |         |
| <50                             | 15 (55.0) | 9 (45.0)   | 0.12    |
| ≥50                             | 255 (65.1)| 169 (49.1)| 0.3     |
| **CD4 (cells/µl)**              |           |            |         |
| ≥350                            | 197 (65.7)| 131 (43.7)| 0.4     |
| 200-349                         | 48 (60.0)| 30 (75.7)  | 0.6     |
| <200                            | 24 (66.7)| 19 (52.8)  | 0.01    |
| **Dyslipidemia**                |           |            |         |
| Yes                             | 117 (66.1)| 76 (42.9)  | 0.04    |
| No                              | 152 (63.6)| 105 (43.9)| 0.3     |
| **Use of lipid-lowering treatment**|        |            |         |
| Yes                             | 2 (66.7) | 1 (33.3)   | 0.8     |
| No                              | 233 (67.4)| 184 (43.6)| 0.9     |

*Note: P values are based on significance levels.*

Table 2: Distribution of characteristics associated with lipohypertrophy, lipoatrophy, and lipodystrophy in HIV-infected patients according to ART treatment status [n (%)].
The selection of confounding factors for lipohypertrophy were: skin color and education (first level), none for the second level, and BMI and CD4 (third level); for lipoatrophy: age and education (first level), smoking and physical activity (second level), and BMI (third level); for lipodystrophy: skin color and education (first level), smoking (second level), and none for the third level. Non-Caucasian participants were at increased risk of lipohypertrophy (RR 1.31 (95% CI 1.02–1.68); P=0.03).

| Lipohypertrophy | Lipoatrophy | Lipodystrophy |
|-----------------|-------------|---------------|
| Gender          | Model 1*    | Model 1†      |
| Male            | 1.00        | 1.00          |
| Female          | 1.00        | 1.00          |
| P value         | <0.001      | <0.001        |
| Age (years)     | 1.01        | 1.00          |
| P value         | 0.06        | 0.90          |

Skin color
Caucasian 1.00 1.00 1.00
Non-Caucasian 1.07 (0.94–1.23) 1.26 (1.12–1.41) 1.13 (1.05–1.21)

Education (years) 1.01 (0.99–1.02) 0.97 (0.98–0.99) 0.99 (0.98–0.99)

Physical activity (min/week) 0.96 (0.98–1.04) 0.99 (0.91–1.09)

Body mass index (kg/m²) 1.07 (1.06–1.09) 1.007 (1.00–1.01)

CD4 (cells/mm³) ≥350 1.00 1.00 1.00

Viral load (copies/mL) ≤50 1.00 1.00 1.00

Time since diagnosis of HIV infection (years) ≤3 1.00 1.00 1.00

* Adjusted for gender and age
* Adjusted for gender, age, and smoking status
** Adjusted for gender, age, smoking status, BMI, CD4, and viral load
† Adjusted for gender, skin color, and education
‡ Adjusted for gender, skin color, education, and physical activity
§ Adjusted for gender, skin color, education, physical activity, and smoking

Table 3: Risk factors for lipodystrophy in HIV–infected patients on antiretroviral treatment (risk ratio and 95% CI).

was markedly affected by biological characteristics, which increased the risk, except by education that was inversely associated. HIV-related characteristics-BMI (P=0.04) and time since the HIV diagnosis (P=0.01) maintained positive associations with lipodystrophy, even after the control for confounding factors.

Table 4 shows the risk factors for lipodystrophy in patients ART naïve, following the same models of control for confounding factors.
compared with Caucasians, independent of skin color and education. Furthermore, after adjusting for skin color, education, and CD4, BMI was associated with higher risk [RR 1.09 (95% CI 1.07–1.11); P<0.001]. As for lipoatrophy, age (P=0.035), education (P=0.001), and physical activity (P=0.046) showed an inverse effect on risk, even after the control for confounding factors. Patients who smoked 20 or more pack-years had 75% the risk (RR=1.75 (95%CI 1.31–2.35) in comparison to never smokers. For lipodystrophy, an independent association was detected only with smoking (P=0.016), but there was no dose-response.

Table 5 describes the metabolic parameters observed in patients on cART who had lipohypertrophy had higher mean levels of nearly all metabolic parameters. Conversely, those with lipohypertrophy had lower mean cholesterol (P<0.001) and LDL-cholesterol (P 0.005) levels. Among ART naïve patients, those with lipohypertrophy had higher total cholesterol (P 0.003), triglycerides (P 0.001), and glucose (P 0.001) levels, while for lipodystrophy the metabolic abnormalities were observed (P 0.047, P 0.02, P 0.02, respectively).

Table 6 shows that use of cART and PI was independently associated with lipohypertrophy, lipoatrophy and lipodystrophy. The use of ART increased 23%, 30%, and 49% the risk of lipodystrophy, lipoatrophy, and lipohypertrophy, respectively, while for PI use they were 15%, 20%, and 23%, respectively, after adjustment for biological, lifestyle, and HIV-related characteristics. Additional analysis showed that

---

### Table 5: Metabolic profile (mean ± SEM) of HIV-infected patients with lipodystrophy**.

| Lipohypertrophy | Cholesterol* | HDL cholesterol* | LDL cholesterol* | Triglycerides* | Glucose* |
|------------------|--------------|------------------|------------------|---------------|---------|
| No               | 179.9 ± 2.2  | 51.0 ± 0.7       | 100.2 ± 1.9      | 150.2 ± 5.9   | 86.1 ± 1.5 |
| Yes              | 195.7 ± 2.2  | 52.7 ± 0.7       | 108.4 ± 1.9      | 185.4 ± 5.8   | 90.2 ± 1.5 |
| P-value          | < 0.001      | 0.09             | 0.002            | < 0.001       | 0.05    |

| Lipoatrophy      | Cholesterol* | HDL cholesterol* | LDL cholesterol* | Triglycerides* | Glucose* |
|------------------|--------------|------------------|------------------|---------------|---------|
| No               | 195.6 ± 2.4  | 52.4 ± 0.8       | 108.8 ± 2.1      | 175.6 ± 6.5   | 89.8 ± 1.6 |
| Yes              | 182.2 ± 2.0  | 51.1 ± 0.7       | 101.1 ± 1.7      | 162.4 ± 5.5   | 87.0 ± 1.4 |
| P-value          | <0.001       | 0.09             | 0.005            | 0.1           | 0.2     |

| Lipodystrophy    | Cholesterol* | HDL cholesterol* | LDL cholesterol* | Triglycerides* | Glucose* |
|------------------|--------------|------------------|------------------|---------------|---------|
| No               | 188.5 ± 3.5  | 52.4 ± 1.1       | 104.8 ± 2.9      | 162.5 ± 9.2   | 86.0 ± 2.3 |
| Yes              | 187.7 ± 1.8  | 51.7 ± 0.6       | 104.2 ± 1.5      | 169.4 ± 4.7   | 87.7 ± 1.2 |
| P-value          | 0.8          | 0.6              | 0.9              | 0.5           | 0.3     |

**Adjusted for age, skin color, smoking status, and time since HIV diagnosis

### Table 6: Modified Poisson regression for risk factors associated with lipohypertrophy, lipoatrophy and lipodystrophy (risk ratio and 95%CI).

| Risk factor                | Lipohypertrophy | Lipoatrophy | Lipodystrophy |
|----------------------------|-----------------|-------------|---------------|
| Antiretroviral treatment (ART) | 1.33 (1.15–1.52)* | 1.33 (1.18–1.50)* | 1.22 (1.13–1.32)* |
| ART+gender                 | 1.34 (1.16–1.54)* | 1.33 (1.18–1.50)* | 1.22 (1.13–1.32)* |
| ART+age (years)            | 1.31 (1.14–1.51)* | 1.34 (1.18 – 1.52)* | 1.22 (1.12–1.32)* |
| ART+skin color             | 1.34 (1.16 – 1.54)* | 1.34 (1.18–1.51)* | 1.23 (1.14–1.33)* |
| ART, complete model#       | 1.49 (1.30 – 1.70)* | 1.30 (1.15–1.47)* | 1.23 (1.13–1.33)* |
| Protease inhibitors (PI)   | 1.16 (1.03–1.31)** | 1.22 (1.10–1.36)* | 1.14 (1.07–1.22)* |
| PI+gender                  | 1.13 (1.00–1.27)** | 1.23 (1.11–1.36)* | 1.14 (1.07–1.22)* |
| PI+age (years)             | 1.15 (1.02–1.30)** | 1.22 (1.10–1.36)* | 1.14 (1.07–1.21)* |
| PI+skin color              | 1.17 (1.04–1.32)** | 1.24 (1.12–1.38)* | 1.15 (1.08–1.23)* |
| PI, complete model#        | 1.23 (1.10–1.38)* | 1.20 (1.08–1.32)* | 1.15 (1.07–1.22)* |

*Adjusted for gender, skin color, smoking status, BMI and CD4.
**P-value<0.001; **P value 0.01 ≤ P ≤ 0.05;  ∆ P value=0.19
thymidine analogs were associated with higher risk of lipohypertrophy (RR=1.47 [95%CI: 1.30-1.36], P<0.001), lipodystrophy (RR=1.35 [95%CI: 1.22-1.50], P<0.001), and lipid abnormalities (RR=1.27 [95%CI:1.20-1.35], P<0.001), independent of gender, skin color, smoking, and CD4. In addition, we estimated that use of PI can be regarded as responsible for 13% of the association of ART and lipodystrophy, and of 11.5% for the thymidine analogs use, independent of gender, skin color, smoking, CD4, and BMI.

Discussion

This study showed that in this population several characteristics associated with lipohypertrophy and lipodystrophy phenotypes were different among those on ART and ART naïve. In addition, it also showed that the lipodystrophy category is not so helpful, since risk factors for lipodystrophy and lipohypertrophy are very different. Although lipodystrophy is more frequent in individuals on ART, this study shows that patients ART naïve were also affected [31] and that clinical outcomes can be attributed to the HIV infection.

Lipodystrophy seems to be mediated, even before the institution of ART, by an increase of inflammatory cytokines resulting from the infection itself [3]. Epidemiological studies suggest that cART and factors not related to therapy aile are potential risk factors for body fat redistribution [6,9]. For instance, among ART naïve patients, the associations between smoking and lipodystrophy, mainly due to the lipodystrophy component, and the inverse relationship between CD4 levels and lipodystrophy can be related to the progressive wasting that commonly accompanies the decrease of CD4. The results of our study agree with those verified in a large multicenter, cross-sectional study [31]. The multi-factorial explanation of lipodystrophy is corroborated in other reports of body fat, outpatient study carried out in the United States, which showed that lipodystrophy was strongly associated with ART and patient-related factors and that lipodystrophy was linked to correlates of immunologic recovery. The multi-factorial explanation of lipodystrophy is corroborated in other reports of body fat changes in HIV-1 infected patients who were not on PI [32], but were taken nucleoside reverse transcriptase inhibitors (NRTI) and no PI [31,33].

Few studies have been conducted among HIV-infected patients who were not on ART and most of the known associations derived from studies on patients on cART. This report among patients on ART from Southern Brazil confirmed the risk of lipohypertrophy associated with female gender [3,13,34], increasing age [31,35], high BMI [31], hyperglycemia [34], and abnormal lipid profile [35,36]. Regarding lipodystrophy in patients on cART, the results of this study were similar to those described for low BMI [6,36,37], reduced LDL cholesterol, and low total cholesterol. Overall lipodystrophy had confirmed associations with age [35], non-Caucasian skin color, BMI [38], and duration of HIV infection [15]. The comparison of findings among patients on cART and ART naïve allows identifying a common pathway for the association of BMI with lipodystrophy. Patients with greater fat deposit may slow or mitigate the loss of adipose tissue.

This study also assessed metabolic profile of HIV-infected patients, on ART and ART naïve, mostly associated with metabolic syndrome [39]. A previous multicenter cohort study reported more frequent lipid abnormalities in HIV-infected individuals than in the general population[40]. However, this study showed that lipid levels vary according to the ART status and that the report without taken into account this condition may under detect the prevalence of metabolic abnormalities [41]. A study conducted with patients on cART in Rwanda, showed higher lipid profiles and blood glucose in patients with lipodystrophy than in those who did not have the condition [13]. This study provided further information since lipid and glucose abnormalities were higher in patients with lipohypertrophy and lower among those with lipodystrophy on cART. However, ART naïve patients who had lipohypertrophy also had higher levels of cholesterol, triglyceride and glucose.

The imbalance of metabolic profile has been attributed to insulin resistance [30], which is increased by ART use, but not exclusively [42]. Sensitivity to insulin is worsen among patients on PI treatment who had lipodystrophy [43] and each additional year of exposure to nucleoside analogue reverse transcriptase inhibitors (NRTI) increased 8% the odds of hyperinsulinemia and 20% for stavudine [42].

There are some potential limitations that should take into account in the interpretation of the results. The cross-sectional design precludes the establishment of causal relationships and may be affected by potential biases. Ascertainment bias, for example, could have biased the diagnosis of clinical outcomes if the observer knew what ART drugs were in use and their adverse effects. However, the diagnosis was based in a combination of objective measurements or the patients’ report of changes in body fat. The data collection was carried out with no information about the hypothesis being tested and what criteria would be used for the diagnosis. However, the study enrolled a large sample size, the data collection was meticulously obtained, all measurements were carried out in duplicate and the average was adopted in the analysis. Finally, the control for confounding factors was based on separated modeling for each clinical outcome and the use of modified Poisson regression was able to provide risk estimates appropriated for the cross-sectional design, what may have mitigated the role of biases. Besides, the simultaneous description of both phenotypes according to the ART status provides information to develop specific interventions to minimize the effect of ART and pathways to investigate causality. The results of this study could be generalized to patients with HIV/AIDS who seek care in the public health system of Porto Alegre, Southern Brazil, and its metropolitan area. Therefore, our patients are alike those from other public health centers, which provide care for most of HIV infected patients.

In conclusion, HIV-associated lipodystrophy occurred in patients with longer duration of HIV infection and on treatment with antiretroviral drugs, in whom metabolic abnormalities, especially dyslipidemia, are frequent and present increased cardiovascular risk. Therefore, these patients should undergo frequent laboratory monitoring and, if indicated, specific treatment should be initiated, since ART use is essential to increase life expectancy and to reduce the burden of disease. However, patients ART naïve were also at increased risk of cardiovascular events due to lipid abnormalities, which could be prevented.

Acknowledgements

This study was supported by grants and scholarships from the CNPq (National Council for Scientific and Technological Development), CAPES (Coordination for the Improvement of Higher Education Personnel), Fundação de Amparo a Pesquisa do Rio Grande do Sul (FAPERGS), and FINEP-HCPA (Fundo de Apoio a Pesquisa, Hospital de Clínicas de Porto Alegre).

The sponsors did not take part in the design or conduct of the study, including data collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

The authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References
1. Paletta FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.

2. Hadigan C, Meigs JB, Korcoran C, Rietschel P, Piecuch S, et al. (2001) Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32: 130-139.

3. Grinspoon SK (2005) Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 118 Suppl 2: 238-245.

4. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, et al. (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37: 613-627.

5. Villaroya F, Domingo P, Estrada V, Lopez-Aldeguer J, Villaroya F, Martinez E (2012) Fat distribution changes in HIV infection. Curr Opin Infect Dis 25: 1-12.

6. Domingo P, Estrada V, Lopez-Aldeguer J, Villaroya F, Martinez E (2012) Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev 14: 112-123.

7. Leow MK, Addy CL, Mantzoros CS (2003) Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 88: 1961-1976.

8. Carr A, Samarás K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 1881-1883.

9. Villaroya F, Domingo P, Giralt M (2005) Lipodystrophy associated with highly active antiretroviral therapy for HIV infection: the adipocyte as a target of antiretroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 26: 88-93.

10. Carr A (2003) HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17 Suppl 1: S141-148.

11. Mullumura E, Stewart A, Rheeder P, Crowther NJ (2007) Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immun Defic Syndr 46: 451-455.

12. Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, et al. (2009) Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immun Defic Syndr 51: 224-230.

13. Diehl LA, Dias JR, Paes AC, Thomazini MC, Garcia LR, et al. (2008) [Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: relation with metabolic syndrome and cardiovascular risk factors]. Arq Bras Endocrinol Metabol 52: 658-667.

14. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, et al. (2005) Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS 19 Suppl 4: S141-21.

15. Bernaards CM, Twisk JW, Snij J, Van Mechem W, Kemper HC (2001) Is calculating pack-years retrospectively a valid method to estimate lifetime tobacco smoking? A comparison between retrospectively calculated time-years and retrospectively calculated pack-years. Addiction 96: 1553-1601.

16. Halmenschlager G, Rossetto S, Lara GM, Roden EL (2009) Evaluation of the effects of cigarette smoking on testosterone levels in adult men. J Sex Med 6: 1763-1772.

17. Cui Q, Carruthers S, McVor A, Small F, Thabane L, et al. (2010) Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. AIDS Res Ther 7: 6.

18. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, et al. (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35: 1381-1395.

19. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, et al. (1995) Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 273: 402-407.

20. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, et al. (2007) Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 116: 1081-1093.

21. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.

22. Bucolo G, David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19: 476-482.

23. Trinder P (1969) Determination of blood glucose using an oxidase-peroxidase system with a non-carboxigenic chromogen. J Clin Pathol 22: 158-161.

24. Gillespie CD, Keenan NL, Miner JB, Hong Y, Centers for Disease Control and Prevention (CDC) (2012) Screening for lipid disorders among adults—National Health and Nutrition Examination Survey, United States, 2005-2008. MMWR Mortal Morb Wkly Rep 61 Suppl: 26-31.

25. Alencastro PR, Wolff FH, Ikeda ML, Schueller-Tresvilo F, Brandão AB, et al. (2012) Diagnostic criteria for lipodystrophy in HIV-infected patients (submitted).

26. Tien PC, Cole SR, Williams CM, Li R, Justman JE, et al. (2003) Incidence of lipodystrophy and lipophypterythroph in the women’s interagency HIV study. J Acquir Immun Defic Syndr 34: 461-468.

27. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome—a new worldwide definition. Lancet 366: 1059-1062.

28. NHANESIII. National Health and Nutritional Examination Survey III: Body Measurements

29. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, et al. (2001) Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15: 1389-1398.

30. Glesby M, Desai A, Erbelding E, Kostman J (1999) High prevalence of impaired glucose tolerance prior to initiating protease inhibitor therapy. In: Sixth Conference on Retroviruses and Opportunistic Infections, Chicago.

31. Saint-Marc T, Partisani M, Pozoiot-Martin I, Bruno F, Rouviere O, et al. (1999) A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13: 1659-1667.

32. Grunfeld C (2008) Understanding the complications of antiretroviral drugs. Clin Infect Dis 47: 575-576.

33. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, et al. (2001) Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357: 592-598.

34. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, et al. (2006) Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immun Defic Syndr 43: 456-466.

35. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, et al. (2003) Incidence of and risk factors for lipodystrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immun Defic Syndr 32: 48-56.

36. Lichtenstein KA (2005) Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immun Defic Syndr 39: 395-400.

37. Alencastro PR, Wolff FH, Oliveira RR, Ikeda ML, Barcellos NT, et al. (2005) Incidence of and risk factors for lipodystrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immun Defic Syndr 32: 48-56.

38. Lisboa MS, de Almeida MA, de Lima RR, et al. (2003) Incidence of cardiovascular disease risk factors in HIV-positive patients—association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1161-1193.

39. Schueller-Tresvilo F, Alencastro PR, Ribeiro PAB, Wolff FH, Ikeda MLR, et al. (2012) Association of Physical Activity with Lipodystrophy Syndrome in HIV-Infected Patients. J AIDS Clin Res 3:177.
42. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, et al. (2005) Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 19: 1375-1383.

43. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, et al. (2001) Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 15: 1993-2000.